4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

A multiple myeloma diagnosis is a life event that can be overwhelming. Get trusted information for every step of your journey. Multiple myeloma can be tricky. That’s because it sometimes has no ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

Multiple myeloma is a rare type of cancer. It starts with the uncontrolled production of plasma cells. These are a type of white blood cell in the bone marrow. Healthy plasma cells make antibodies ...

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and new thinking on the role of immunological aging, especially how it affec ...

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood Journal , 2024; DOI: 10.1182/blood.2024025945 Cite This Page : ...

NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether. The recent ...

Dr Martin Kaiser’s group aims to design gentler, tailored therapies for patients with multiple myeloma, an immune cell cancer of the bone marrow. I joined the team in December 2020 and I am involved ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma last week, J&J has wasted little time hitting back with new data on its ...

Were exposed to pesticides. We do not know what causes MGUS. There may be a link to autoimmune diseases, genetics, or environmental factors. Like multiple myeloma, MGUS starts in a type of white blood ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti has once again mounted a ...